Aerobic glycolysis or the Warburg effect contributes to cancer cell proliferation; however, how this glucose metabolism pathway is precisely regulated remains elusive. Here we show that receptor-interacting protein 1 (RIP1), a cell death and survival signaling factor, regulates mitochondrial oxidative phosphorylation and aerobic glycolysis. Loss of RIP1 in lung cancer cells suppressed peroxisome proliferator-activated receptor c coactivator-1a (PGC-1a) expression, impairing mitochondrial oxidative phosphorylation and accelerating glycolysis, resulting in spontaneous DNA damage and p53-mediated cell proliferation inhibition. Thus, although aerobic glycolysis within a certain range favors cancer cell proliferation, excessive glycolysis causes cytostasis. Our data suggest that maintenance of glycolysis by RIP1 is pivotal to cancer cell energy homeostasis and DNA integrity and may be exploited for use in anticancer therapy. A cell's metabolism is optimized for its function and adapts to environmental changes; therefore, it is pivotal to differentiation, proliferation, survival and death. In the presence of ample oxygen, cancer cells prefer glycolysis over mitochondrial respiration for energy supply, which is known as the Warburg effect or aerobic glycolysis.
A cell's metabolism is optimized for its function and adapts to environmental changes; therefore, it is pivotal to differentiation, proliferation, survival and death. In the presence of ample oxygen, cancer cells prefer glycolysis over mitochondrial respiration for energy supply, which is known as the Warburg effect or aerobic glycolysis. 1, 2 Although aerobic glycolysis was originally thought to complement impaired mitochondrial respiration, recent investigations suggest that it is a driving force in cancer cell transformation and proliferation. 3, 4 In coordination with the tricarboxylic acid cycle and mitochondrial respiration, cancer cells increase glycolysis to support their rapid proliferation. This 'metabolic transformation' in cancer cells not only meets their energy requirements but also provides the building blocks for synthesis of biomass and for maintenance of redox homeostasis. 5, 6 Thus, the metabolic transformation is believed to offer cancer cells a selective growth advantage compared with their normal counterparts and to contribute to drug resistance. Many oncogenes such as c-Myc and Akt, and tumor suppressors such as p53 are involved in the regulation of glycolysis and mitochondrial metabolism, serving as evidence of the necessity for metabolic adaptation in cancer cells. 7, 8 However, how metabolic transformation is precisely regulated needs further elucidation.
Receptor-interacting protein 1 (RIP1) is a serine/threonine kinase with functions in cell proliferation, survival and death. [9] [10] [11] The role of RIP1 in cell survival is achieved mainly through its function as an adaptor in signal pathways, such as NF-kB and PI3K/Akt, that suppress apoptosis. The kinase activity of RIP1 is involved in programmed necrosis or necroptosis. 12 Although RIP1 can translocate to the mitochondria in certain circumstances and can modulate ADP/ ATP exchange and the production of mitochondrial reactive oxygen species (ROS), [13] [14] [15] [16] whether RIP1 regulates cell energy homeostasis is unknown.
In an attempt to investigate the role of RIP1 in cell proliferation, we uncovered a function for this protein in regulating mitochondrial respiration. RIP1 knockdown resulted in downregulation of PGC-1a, mitochondrial oxidative phosphorylation (OXPHOS) defect and accelerated glycolysis, leading to spontaneous DNA damage and proliferation suppression. Our results suggest that RIP1 holds glycolysis within a suitable range to maintain cancer cell energy homeostasis and DNA integrity. Thus, intervention in the RIP1-mediated glycolysis pathway may be exploited for use in anticancer therapy.
Results
Knockdown of RIP1 induces p53-dependent inhibition of lung cancer cell proliferation. Two lentiviral vectors harboring distinct shRNA sequences targeting RIP1 mRNA were used to create stable knockdown lung cancer cells. Figure 1b) . The growth of tumors derived from control vector-transduced A549 cells subcutaneously injected into nude mice proliferated continuously as in those from parental cells (data not shown), whereas the growth of RIP1 knockdown tumors was retarded, resulting in smaller tumor size or even tumor regression (Figure 1c ). These results demonstrate that RIP1 downregulation inhibited the proliferation of lung cancer cells in vitro and in vivo.
RIP1 has been shown to inhibit p53 to promote cell cycle progression. 17 Indeed, in A549 and H460 cells that have wild-type p53, RIP1 knockdown elevated the protein expression of p53 together with its targets p21 and MDM2 (Figure 1d and Supplementary Figure 1c) . With RIP1 stable knockdown, p21 induction was also seen in H23 cells with a p53 mutation (M246I) capable of activating p21 expression, 18 but p21 induction was not observed in p53 inactive mutant (R273L) H2009 and p53 null H1299 cells (Supplementary Figure 1c) . Transient knockdown of p53 with siRNA in RIP1-deficient cells attenuated p21 expression (Figure 1e and Supplementary Figure 1d) . The suppression of p53 boosted the proliferation of RIP1 knockdown cells but not that of control A549 cells (Figure 1f) . Further, the inhibition of cell proliferation with RIP1 knockdown was seen in H23 but not in H2009 and H1299 cells (Supplementary Figure 1e) . In contrast, the expression of the proapoptotic p53 target gene Bax was unchanged in RIP1 knockdown cells, and no cleavage of PARP, a marker of apoptosis, was observed ( Supplementary  Figure 2f) . These data indicate that increased expression of p53 and p21, without apoptosis, was primarily responsible for the inhibition of proliferation in RIP1 knockdown cells. Because RIP1 is an important component in NF-kB activation induced by distinct stimuli, downregulation of RIP1 may impair activation of this pathway, which in turn may impair cell proliferation. However, this is very unlikely because constitutive NF-kB activity remained unchanged in RIP1 KD cells (Supplementary Figure 1g) .
Increased spontaneous DNA damage activates p53 in RIP1 knockdown cells. One common cause for p53 activation is DNA damage. 19 We observed increased phosphorylation of H2AX (serine 139, gH2AX), a widely used marker for DNA double-strand breaks, 20, 21 in RIP1 knockdown lung cancer cells (Figure 2a, Supplementary Figures 2a and  2b) . Immunofluorescence showed that the majority of RIP1 knockdown cells were positive for the formation of gH2AX foci, whereas only a small portion of control cells exhibited gH2AX foci (Figure 2b ). Although ATR target CHK1 only showed mild activation, consistent robust activation of ATM and its downstream target CHK2 was detected (Figure 2a and Supplementary Figure 2a) , indicative of elevated DNA double-strand breaks in the RIP1 knockdown cells. Suppression of ATM activation with ATM/ATR inhibitors CGK733 and caffeine 22 used at low concentrations (relatively specific to ATM), or ATM inhibitor Ku55933, effectively reduced p53 and p21 expression (Figure 2c and data not shown). These results indicate that DNA damage was responsible for p53 activation in the RIP1 knockdown cells.
DNA damage can result from increased endogenous DNA-damaging agents such as ROS or from decreased DNA repair. 23 In RIP1 knockdown cells, the ATM-mediated DNA damage response pathway was intact (Figure 2a Figure 2c) and ROS scavenger N-acetyl cysteine (NAC) treatment did not reduce gH2AX levels (Supplementary Figure 3d) , suggesting that increased DNA-damaging agents are probably not the major source of DNA damage in RIP1 knockdown cells. Therefore, we used 
RIP1 knockout (RIP1
À / À ) mouse embryonic fibroblasts (MEFs) to investigate whether RIP1 deficiency reduces DNA repair capacity. Interestingly, when MEF cells were nonconfluent, gH2AX was barely detected in both wild type (WT) and RIP1
À / À MEFs; however, when cells were fully confluent and thus not actively cycling, RIP1
À / À but not WT MEFs showed elevated gH2AX level (Figure 2d ). Nonconfluent cells were treated with the topoisomerase II inhibitor adriamycin to induce DNA double-strand breaks and further observed for DNA repair response with detection of gH2AX. The WT cells repaired most DNA damage within 16 h, while RIP1
À / À cells showed minimal removal of DNA breaks. Partial restoration of RIP1 expression in RIP1
À / À cells restored DNA repair capacity (Figure 2e ). This result suggests that a moderate RIP1 expression level in MEFs is sufficient to maintain DNA repair capacity, which is similar to the requirement for RIP1 expression in basal (Supplementary Figure 1g) and TNFainduced NF-kB activation. 24 The persistent high gH2AX levels in RIP1
À / À cells were not due to cell death (Supplementary Figure 2e) . In concert with these findings in MEFs, RIP1 knockdown rendered cells more vulnerable to a variety of DNA double-strand break inducers including anticancer agents, adriamycin, camptothecin, and the cigarette smoke carcinogen benzo[a]pyrene diol epoxide (BPDE) (Figure 2f and Supplementary Figure 2f) . These data imply that downregulation of RIP1 impaired DNA repair capacity, which resulted in increased spontaneous DNA damage.
Excessive glycolysis suppresses DNA repair in RIP1 knockdown cells. Despite that RIP1 knockdown cells proliferated more slowly than control cells, we consistently observed that acidification of the culture medium with knockdown cells occurred more quickly, an indication of accelerated mitochondrial metabolism that produces CO 2 or enhanced glycolysis that releases lactate. Although both A549 and H460 are glycolytic cells, 25 there was a marked increase in lactate release in media after RIP1 downregulation ( Figure 3a and Supplementary Figure 3a) . To determine whether excessive glycolysis elicits spontaneous DNA damage, RIP1 knockdown cells were treated with low concentrations of 2-DG and oxamate to partially suppress glycolysis. Both inhibitors reduced the activation of ATM, CHK2 and gH2AX in RIP1 knockdown cells (Figure 4a and Supplementary Figures 4a and 4b ), indicating that excessive glycolysis contributes to DNA damage and activates the DNA damage response. Note that the very low concentrations of inhibitors that stimulated RIP1 knockdown cell growth also alleviated DNA damage (Supplementary Figure 4c) . NAD þ is essential for DNA repair, and its deficiency has been shown to induce spontaneous DNA damage. 26, 27 Because glycolysis converts NAD þ to NADH, enhanced glycolysis may lead to additional utilization of NAD þ that decreases the cellular NAD þ pool. 28, 29 Consistent with this notion, there was a 20-40% reduction of NAD þ in RIP1 knockdown cells compared with that in control cells (Figure 4b ). Cell fractionation showed that the most severe reduction in NAD þ level occurred in the nuclei (Supplementary Figure 4d) . RIP À / À MEFs also contained much lower cytosolic NAD þ compared with that in WT cells (Supplementary Figure 4e) . To replenish cellular NAD þ , RIP1 knockdown cells were cultured in medium with nicotinamide (Nam), a precursor of NAD þ . 26 Nam addition reduced gH2AX and p21 levels and increased proliferation in RIP1 knockdown cells but did not affect the proliferation of control cells (Figures 4c and d ). These data demonstrate that excessive glycolysis leads to decreased cellular NAD þ levels, which may partially be responsible for defective DNA repair and proliferation inhibition in RIP1 knockdown cells.
RIP1 regulates PGC-1a expression. To investigate the mechanism underlying the metabolic shift, a cDNA array analysis was performed and the gene identified with the highest reduction in RIP1 knockdown cells was PGC-1a, an important regulator of mitochondrial biogenesis and cell metabolism. The result was confirmed by RT-PCR and western blot (Figure 5a and Supplementary Figure 5a) . In contrast, the expression of PGC-1b, another member of the PGC family, was not altered (Figure 5a ). In addition, in wild-type A549 cells, severe glucose starvation (o0.5 mM, supplied only by that contained in 10% fetal bovine serum) induced downregulation of PGC-1a, which was restored with addition of glucose to the level of that found in normal culture medium. RIP1 knockdown suppressed the basal level of PGC-1a and attenuated restoration of PGC-1a expression with glucose replenishment (Figure 5b ), suggesting that RIP1 is involved in glucose-induced PGC-1a expression.
To further confirm that RIP1 regulates PGC-1a expression, RIP1 (Xp-RIP1) was overexpressed in HEK293 cells together . These results signify that the DDD and the kinase death mutants of RIP1 cannot operate as dominant negative mutations to block endogenous RIP1 function for PGC1a expression; furthermore, the DD and kinase activity of RIP1 are not required for PGC-1a induction. Collectively, these data indicate that RIP1 regulates PGC-1a transcription. RIP1 mediates Akt signaling, and Akt has been shown to repress PGC-1a expression. 30 However, both basal and growth factor-induced Akt activation were not altered in RIP1 knockdown cells (data not shown). p53 has also been shown to suppress PGC-1a expression, 31 and p53 was elevated in RIP1 knockdown cells (Figure 1a and Supplementary Figure 1a) . However, suppression of p53 in RIP1 knockdown cells did not elevate the expression of PGC-1a (Supplementary Figure 5c) . These results demonstrate that RIP1 knockdown-mediated PGC-1a suppression does not involve p53 or Akt.
Downregulation of PGC-1a impairs mitochondrial OXPHOS in RIP1 knockdown cells. OXPHOS dysfunction is known to lead to compensatory glycolysis, and inhibition of mitochondrial respiration enhances glycolysis. 25 Thus, we sought to determine whether downregulation of PGC-1a impaired OXPHOS in RIP1 knockdown cells. Consistent with the reduced expression of PGC-1a, the expression of the mitochondrial electron transfer chain components cytochrome c (cyt c) and cytochrome c oxidase IV (COX IV), both PGC-1a target genes, 32 were decreased in RIP1 knockdown cells (Figure 6a and Supplementary Figure 6a) . Microarray data showed that RIP1 knockdown caused a massive expression reduction in components in all the complexes of the electron transport chain (Supplementary Table 1 ). Many of these genes are targets of the nuclear respiratory factor (NRF)-1/2 or estrogen-related receptor (ERR) a/g, for which PGC-1a is a co-activator. [33] [34] [35] Accordingly, the complex IV enzyme activity was significantly lower in RIP1 knockdown cells (Figure 6b and Supplementary  Figure 6b ). Both mitochondrial mass and DNA content in RIP1 knockdown cells were comparable to that in control cells (Supplementary Figures 6c and 6d) . When cells were cultured in low glucose (glucose supplied only in 10% serum), the majority of control cells, but few RIP1 knockdown cells, survived (Figure 6c and Supplementary Figure 6e) . Replenishing the medium with glucose supported the growth of both control and RIP1 knockdown cells. However, the addition of galactose, which forces cells to rely on mitochondrial OXPHOS for energy production, 36 did not rescue RIP1 knockdown cells to those levels observed in controls (Figure 6c and Supplementary Figure 6e) . Thus, RIP1 knockdown cells were unable to efficiently use galactose to sustain cell growth when compared with control cells, indicating reduced OXPHOS function. 36 Finally, partial restoration of PGC-1a in RIP1 knockdown cells increased the expression of cyt c, reduced gH2AX and promoted cell proliferation (Figures 6d and e) , suggesting that PGC-1a suppression mediated the mitochondrial OXPHO defect in these cells.
Discussion
This study provides evidence that RIP1 regulates glucose metabolism. Knockdown of RIP1 resulted in OXPHOS defect and excessive glycolysis, leading to spontaneous DNA damage and suppression of cell proliferation mediated by p53. We identified PGC-1a as a key mediator in the defect of mitochondrial OXPHOS. Furthermore, excessive glycolysis rendered cells more vulnerable to cytotoxicity induced by genotoxic agents and glycolysis inhibitors. Our data suggest that, although the Warburg effect favors cancer cell proliferation, maintenance of glycolysis in an optimal range by RIP1 is pivotal for cancer cell energy homeostasis and for maintaining DNA integrity, and intervention in this pathway may be exploited for use in anticancer therapy (Figure 6f ). PGC-1a controls mitochondrial biogenesis and metabolism and is involved in diverse diseases including diabetes, heart failure, aging and cancer. 37, 38 Here we show that RIP1 positively regulates PGC-1a transcription. Although there was no loss of mitochondrial mass or DNA content in RIP1 knockdown cells, there was a marked reduction in components of the electron transfer chain including cyt c and COX IV, leading to compromised enzyme activity that may account for the defect in mitochondrial OXPHOS. Similar findings in PGC-1a expression and mitochondrial function were reported recently in vivo.
31 RIP1 appears to be necessary but insufficient to maintain the level of PGC-1a, as seen upon glucose starvation, PGC-1a decreased in the presence of RIP1. Upon lethal stimulation, cellular energy status is the key for a cell's decision to proceed towards the processes of either apoptosis or necroptosis. Therefore, it remains to be determined whether PGC-1a participates in the RIP1-mediated cell death decision. The mechanism by which RIP1 controls PGC1a expression is still unclear. RIP1 mediates pathways that have been shown to control the transcription of PGC-1a. 39 Alternatively, as a nuclear protein, 40 RIP1 may act as a co-activator for PGC-1a transcription.
Although aerobic glycolysis serves cancer cells in proliferation and survival through maintenance of biosynthesis and redox homeostasis, excessive glycolysis may be harmful to cancer cells. For example, oncogene hyperactivationenhanced aerobic glycolysis was associated with endoplasmic reticulum stress and demise in murine Ba/F3 pro-B-cells. 41 Currently, it is unclear whether there is a beneficial threshold for glycolysis in cancer cells. We demonstrated that RIP1 knockdown in lung cancer cells impaired mitochondrial OXPHOS, forcing the cells to rely heavily on glycolysis for energy supply. Meanwhile, excessive glycolysis resulted in DNA damage-mediated p53 activation and p53-dependent proliferation inhibition. Thus, in cancer cells with an established energetic homeostasis favoring a glycolytic phenotype, shifting toward increased glycolysis may not necessarily endorse but rather could suppress proliferation.
Cancer cells exhibit inherent genomic instability that is largely attributed to increased DNA damaging factors such as ROS and defects in DNA repair. Given that metabolic transformation is a hallmark of cancer cells, the contribution of aerobic glycolysis to genomic instability in cancer cells deserves further investigation. The glycolysis inhibitor 2-DG has long been known to reduce oxidative DNA damage, 42 and recently it was shown to inhibit ATM activation and gH2AX in human lymphoblastoid cells, presumably by reducing ROS production. 43 However, 2-DG was also reported to increase radiation-induced DNA damage. 44, 45 Further, aerobic glycolysis is believed to help cancer cells manage elevated oxidative stress level. 5 In our studies, basal ROS production was not altered in RIP1 knockdown cells. However, excessive glycolysis seemed to perturb NAD þ metabolism, which is an essential cofactor for DNA repair enzymes such as the Sirtuin and PARP family members. 46 Therefore, excessive glycolysis may contribute to genomic instability in cancer cells and maintenance of glycolysis in an optimal range could be important for DNA repair capacity.
An important question to answer is whether downregulation of RIP1 can be exploited in cancer therapy. It has been documented that downregulation of RIP1 sensitizes cancer cells to tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL). 47, 48 These effects were mainly attributed to a survival disadvantage because RIP1 downregulation blunts therapeutic-induced NF-kB activation. 49 However, the role of RIP1 in cancer therapy is complicated by evidence demonstrating the pivotal role of RIP1 in both apoptosis and necroptosis. 50 Thus, the consequences of RIP1 knockdown combined with other treatments could be cell type-specific and context-dependent, and could also depend on the type and dose of the treatment. 51 Of note, Although genotoxic anticancer drugs primarily induce various types of DNA damage, they also alter other cellular activities including metabolism. 52 Here we show that RIP1 knockdown renders cancer cells with wild-type p53 more vulnerable to both DNA damaging anticancer agents and glycolysis inhibitors, supporting the targeting of RIP1 as an approach to use in combined cancer therapy. Remarkably, because excessive glycolysis may restrain cancer cell proliferation, limited glycolysis inhibition may be detrimental. Thus, it would be critical to monitor RIP1 expression and the effectiveness of glycolysis suppression during therapy targeting glycolysis.
In summary, our results show a function for RIP1 in cell metabolism through the regulation of PGC-1a expression. Although the Warburg effect favors cancer cell proliferation, maintenance of glycolysis in a suitable range by RIP1 is pivotal for cancer cell energy homeostasis and for maintaining DNA integrity, and intervention in this pathway could be exploited for use in anticancer therapy. Given the broad function of PGC-1a in mitochondrial metabolism and in diverse diseases, it is of great interest to investigate the role of RIP1 in related disorders.
Materials and Methods
Reagents. ATM/ATR (Ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-related) kinase inhibitor CGK733 was from Calbiochem (La Jolla, CA, USA). Benzo[a]pyrene diol epoxide (BPDE) was purchased from NCI Chemical Carcinogen Reference Standards Repository. All other chemicals were from Sigma (St. Louis, MO, USA). The antibodies used were anti-MDM2, anti-p21(BD Biosciences, San Jose, CA, USA), anti-cytochrome c (BioLegend, San Diego, CA, USA), anti-phospho-CHK1, anti-phospho-CHK2, anti-cytochrome c oxidase IV, anti-phospho-H2AX (serine 139, gH2AX; rabbit), anti-p53 (rabbit; Cell Signaling, Beverly, MA, USA), anti-phospho-ATM (Epitomics, Burlingame, CA, USA), antip53 (mouse), anti-Xpress (Omni-probe), anti-GAPDH (glyceraldehyde phosphate dehydrogenase; Santa Cruz, Santa Cruz, CA, USA), anti-b-actin, anti-b-tubulin (Sigma); anti-PGC-1a and anti-gH2AX (mouse) (Millipore, Billerica, MA, USA).
Cell culture. Lung cancer cells line A549, H460, H23, H2009 and H1299 were from American Typical Culture Center (ATCC, Manassas, VA, USA) and were maintained in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine and antibiotics (100 mg/ml of penicillin and 100 U/ml of streptomycin). Wild-type and RIP1 knockout (RIP1 À / À ) mouse embryonic fibroblasts (MEFs) have been described previously. 53 MEFs and HEK293 cells were cultured in DMEM containing high glucose, 10% FBS and antibiotics. RPMI 1640 Medium without glucose was purchased from MP Biomedicals (Solon, OH, USA). /well) were seeded in 0.6% soft agar in triplicate. After 10 days, four random fields of cell colonies from each well were photographed, counted and expressed as colonies per field.
Western blot. Cell lysate was prepared with M2 buffer (20 mM Tris-HCl, pH 7.6, 0.5% NP-40, 250 mM NaCl, 3 mM ethylenediaminetetraacetic acid, 3 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 20 mM b-glycerophosphate, 1 mM sodium vanadate and 1 mg/ml leupeptin). Protein concentration was determined with Bio-Rad Bradford assay reagent. Protein samples were separated with SDS-PAGE and transferred to polyvinylidene fluoride membrane. The membrane was blocked with 5% nonfat milk in PBS with 0.5% Tween-20, incubated with primary and second antibodies, and visualized with enhanced chemiluminescence reagent (Millipore). The approximate positions (kDa) of prestained protein standards (Bio-Rad, Hercules, CA, USA) were indicated on the right of the blots. In some experiments, the band density was quantified with NIH ImageJ software (NIH, Bethesda, MD, USA), normalized to corresponding loading control, and then the fold change was shown.
Transfection, RNA interference and reporter assay. SmartPool siRNAs were purchased from Thermo Scientific (Waltham, MA, USA) and transfections (10 nM) were performed with INTERFERin (Polyplus Transfection, New York, NY, USA). Transient plasmid transfection was carried out using Fugene HD (Promega, Madison, WI, USA). Xpress-tagged pcDNA-RIP1 (Xp-RIP1) and its death domain (DD) deletion (DDD) and kinase death (K45A) mutants and NF-kB luciferase reporter plasmid have been previously described. 53 pcDNA-PGC-1a plasmid was purchased from Addgene (Cambridge, MA, USA) and was deposited by Dr. Bruce M. Spiegelman (Harvard Medical School). 54 PGC-1a promoter luciferase construct ( À 992 to þ 90 bp on pGL3 vector) was a kind gift from Dr. Akiyoshi Fukamizu (University of Tsukuba, Japan). 55 For RIP1 overexpression and reporter assay in HEK293 cells, PGC-1a promoter construct was cotransfected with various amounts of pcDNA-RIP1 together with a b-galactosidase expressing vector to monitor transfection efficiency. The amounts of plasmids were kept constant with addition of pcDNA3.1 control vector. Eighteen hours post tranfection, cell lysate was prepared for luciferase and b-galactosidase activity assays using reagents from Promega (Fitchburg, WI, USA). For RIP1 knockdown, reporter assay was carried out 24 h after transfection of PGC-1a promoter construct. Luciferase readings were normalized to that of b-galactosidase and results were expressed as relative activity against control.
RNA extraction, reverse transcription and polymerase chain reaction. Total RNA was isolated with RNeasy kit (Qiagen, Valencia, CA, USA) or Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using a reverse transcription kit (Promega). The PCR conditions for PGC-1a and PGC-1b were 95 1C, Immunofluorescence. Cells were seeded on cover slide and fixed with cold methanol. Subsequently, cells were permeabilized with 0.5% Triton X-100 in PBS for 5 min, blocked with 5% normal donkey serum for 2 h, followed by incubation with rabbit anti-gH2AX (1 : 200) overnight at 4 1C. The slide was further incubated with Alexa Fluor 680-labeled donkey anti-rabbit secondary antibody (Invitrogen; 1 : 500) for 2 h, and then mounted with Fluormount-G (SouthernBiotech, Birmingham, AL, USA) with DAPI (4 0 , 6-diamidino-2-phenylindole) to stain nuclei. Images of the cells were captured using a fluorescence microscope (Carl Zeiss, Germany).
Lactate production. Cells were seeded in triplicate overnight and then incubated with fresh medium containing 1% FBS for 24 h. Lactate concentration in culture medium was determined using lactate assay kit from BioVision (BioVision, Milpitas, CA, USA) and normalized to total cellular protein.
Lactate dehydrogenase activity assay. Cellular LDH activity was determined using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit from Promega. Cells were lysed in M2 buffer, total protein concentrations were measured and then equal amounts of lysates was used for the reaction. Results were expressed as relative activity against control.
Glucose consumption. Equal numbers of cells were seeded in triplicate overnight and then incubated with fresh medium for 24 h. Glucose concentration in culture medium was measured with an assay kit from BioVision. Glucose consumption was calculated by subtraction of glucose amount in medium with cells from that of control without cells in the same plate and then normalized to total cellular proteins.
ATP production. Equal number of cells were seeded in triplicate overnight and then incubated with fresh medium for 24 h. ATP was measured in cell lysates with equal amounts of protein with an ATP assay kit from BioVision.
Cell fractionation and detection of cellular NAD
þ . Cells were first suspended in hypotonic buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT and 0.5 mM PMSF) before addition of detergent (NP-40) to a final concentration of 0.5% followed by homogenization. Nuclei were precipitated by centrifugation at 300 Â g for 10 min at 4 1C. The supernatant was reserved as cytoplasmic fraction. Cytosolic fraction was obtained by further centrifuging the cytoplasmic fraction at 14 000 Â g for 20 min at 4 1C. Total NAD and NADH were determined with NAD/NADH quantification kit from ScienCell Research Laboratories (Carlsbad, CA, USA) or BioVision according to the manufacture's instructions. Total cell lysates were prepared with the extract buffer provided with the kit. For measurement of NADH, cell lysate was heated at 60 1C for 30 min to decompose NAD þ . NAD þ levels were calculated by subtracting NADH concentration from that of total NAD. Results were normalized to protein concentrations and expressed as relative levels against control.
Detection of reactive oxygen species. Dichlorodihydrofluorescein diacetate (CM-H 2 DCFDA, 5 mM; Invitrogen) was added into the culture medium 30 min before collecting cells. The fluorescence intensity was detected using a fluorescence plate reader and normalized to total cellular proteins.
Mitochondrial mass. Cells were stained with 50 nM of MitoTracker (Invitrogen) for 30 min in cell culture incubator. Cells were then collected by trypsinization, fixed in 3.7% formaldehyde for 15 min at 37 1C and subjected to flow cytometry analysis (FACSCalibur, BD Biosciences).
Mitochondrial DNA content. Mitochondrial DNA content was determined with quantitative real-time PCR (qPCR) using the method and primers described by Karamanlidis et al. 56 Total DNA was isolated by proteinase K digestion and ethanol precipitation. qPCR was performed with the ABI PRISM 7900HT. The ratio of cytochrome c oxidase I (COXI) to 18S was reported, although similar results were obtained with 16S to 18S ratios (data not shown).
Mitochondrial complex IV enzyme activity. Cell extract was prepared and enzyme activity determined using an assay kit (ab109909) from Abcam (Cambridge, MA, USA) according to the manufacturer's protocol. The amount of lysate used was 15 mg for A549 and 30 mg for H460. The results were further expressed as relative level with control as 1.
